# NeoPACT (NCT03639948)

> Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03639948
- Phase: PHASE2
- Status: UNKNOWN
- Sponsor: University of Kansas Medical Center
- Conditions: Triple-negative Breast Cancer
- Interventions: Carboplatin; Docetaxel; Pembrolizumab; Pegfilgrastim
- Enrollment: 120
- Primary outcome: Pathological Complete Response (pCR) Rate

## Commentary we found

- YouTube: 15
- Podcasts: 15
- X threads: 8

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=neopact-nct03639948

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03639948", "email": "<work email>"}; the inbox owner confirms by the emailed link.